DBV Technologies S.A.
DBVTBiotechnology
$10.29−3.38%As of Oct 29vs prior close
- Market cap
- $646.7M
- P/E (TTM)
- –
- From 52W high
- −58.07%
- EPS (LTM)
- -$0.61
- Revenue (LTM)
- $3.7M
- Net margin
- -5547.30%
- Dividend yield
- 0.00%
Nomior Score
22
Distressed LaggardSpeculativeBottom 9% of the scored universe
Growth51
Quality21
Value41
Momentum30
Resilience30
Growth
−14.77%revenue a year over 6 fiscal years
YE19 $14.7MLTM $3.7M
Connections
Revenue to profitQ3 YE26
The operating loss was 4050% of revenue, wider by 2825 pts on a year.
Latest resultsThird Quarter 2026
- Net loss
- $64.5 million
DBV submitted its Biologics License Application to the FDA for the VIASKIN Peanut Patch in children and requested Priority Review, while accelerating commercial readiness. Operating expenses rose sharply across research, sales and administrative spending, and the net loss was larger than a year earlier. The company says its cash funds operations into the third quarter of next year, but it has substantial doubt about its ability to continue as a going concern and will need additional capital.
Who owns it
1tracked portfolio